ReviewContrast media & molecular imaging2022
Antigallbladder Carcinoma Activity Analysis of a New Nanometer Drug Delivery System Based on Data Acquisition.
Review in Contrast media & molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Retracted: Antigallbladder Carcinoma Activity Analysis of a New Nanometer Drug Delivery System Based on Data Acquisition.Contrast media & molecular imaging · 2023Article
Corrections and comments
- Retraction · 2023-10-04Computer-Aided Content or Computer-Generated Content · Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Peer Review · Informed/Patient Consent - None/Withdrawn · Investigation by Journal/Publisher · Investigation by Third Party · Lack of IRB/IACUC Approval and/or Compliance · Paper Mill · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to solve the problem of the application of data acquisition in the new nanometer drug delivery system of microscope, a research of antigallbladder carcinoma activity analysis was proposed. Gallbladder carcinoma (GBC) is a common malignant tumor in biliary tract diseases. Due to the lack of specific clinical manifestations in the early stage, GBC has the shortcomings of the hidden onset, the difficult diagnosis, and the high misdiagnosis rate. GBC ranks in the top position among the most common tumors of the digestive system worldwide. The preoperative diagnosis rate is low, and the incidence of accidental gallbladder carcinoma is gradually increasing. Domestic gallbladder carcinoma related to cholecystectomy is not sensitive to radiotherapy and chemotherapy. Surgical resection is still the only effective method for the treatment of accidental gallbladder carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.